KRAS and non-small cell lung carcinoma: The phase III KEYNOTE-042 trial that demonstrated an OS benefit of pembrolizumab in the first-line setting versus platinum-based chemotherapy in patients with advanced NSCLC with PD-L1 expression ≥ 1%, evaluated in an exploratory analysis, the association between KRAS status and efficacy to ICPI.